Product nameAnti-Cardiac Troponin I antibody
See all Cardiac Troponin I primary antibodies
DescriptionGoat polyclonal to Cardiac Troponin I
Tested applicationsSuitable for: IHC-FoFr, IHC-Fr, WB, ELISAmore details
Species reactivityReacts with: Mouse, Human
Full length native cardiac troponin I protein (purified) (Human)
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferPreservative: 0.09% Sodium Azide
Constituents: PBS, pH 7.4
Concentration information loading...
PurityIon Exchange Chromatography
Our Abpromise guarantee covers the use of ab56357 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-FoFr||Use at an assay dependent concentration. PubMed: 29403069|
|IHC-Fr||Use at an assay dependent concentration.|
|WB||Use at an assay dependent concentration.|
|ELISA||Use at an assay dependent concentration.|
FunctionTroponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
Involvement in diseaseDefects in TNNI3 are the cause of cardiomyopathy familial hypertrophic type 7 (CMH7) [MIM:613690]. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
Defects in TNNI3 are the cause of cardiomyopathy familial restrictive type 1 (RCM1) [MIM:115210]. RCM1 is an heart muscle disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function.
Defects in TNNI3 are the cause of cardiomyopathy dilated type 2A (CMD2A) [MIM:611880]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
Defects in TNNI3 are the cause of cardiomyopathy dilated type 1FF (CMD1FF) [MIM:613286]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
Sequence similaritiesBelongs to the troponin I family.
- Information by UniProt
- cardiac muscle antibody
- Cardiac troponin I antibody
- cardiomyopathy, dilated 2A (autosomal recessive) antibody
This product has been referenced in:
- Li Y et al. Genetic targeting of Purkinje fibres by Sema3a-CreERT2. Sci Rep 8:2382 (2018). IHC-FoFr ; Mouse . Read more (PubMed: 29403069) »
- Ingason AB et al. Angiogenesis precedes cardiomyocyte migration in regenerating mammalian hearts. J Thorac Cardiovasc Surg 155:1118-1127.e1 (2018). Read more (PubMed: 29452461) »